We use non-essential cookies (including anonymous analytics) to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential for our platform to work and help us to provide you with the best experience possible. You can accept or reject our non-essential cookies and change your mind at any time. To learn more, please read our cookies policy.

Update cookie preferences

Call for equal access to Niraparib for women in Northern Ireland

03 September 2018

pill niraparib

16th January 2019

UPDATE: Women in Northern Ireland now have access to Niraparib, and the first patients in Northern Ireland have received the drug.

3rd September 2018

This year the PARP inhibitor Niraparib has been approved for use throughout much of the UK, giving hope to thousands of women with recurrent, platinum-sensitive ovarian cancer. However, it is not yet available in Northern Ireland. 

We are calling on the Northern Ireland Department of Health to give women equal access to this ground-breaking, life-extending treatment. 

What is Niraparib?

Niraparib is a PARP inhibitor. This means it blocks the action of enzymes called PARP-1 and PARP-2 that help to repair any damaged DNA in cells when they divide to make new cells. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and the cells die.

What benefits does it have for women with ovarian cancer?

When researchers trailed Niraparib on women with ovarian cancer they observed two important things:

  • Women lived a significantly longer time without their disease worsening 
  • There was a significantly increased  time between treatments, meaning a longer chemotherapy-free interval 

These two points represent a huge step forward for women with recurrent ovarian cancer, where options are limited, and very little progress has been made over the last 40 years.

Delaying the spread of the disease means women can feel better and healthier for longer, experiencing reduced symptoms. Furthermore, the increase in time between rounds of chemotherapy, combined with the fact that Niraparib is taken at home in pill form, means fewer trips to hospital to receive treatment. 

The number of hospital visits all cancer patients have to endure can greatly disrupt day-to-day life, making it very difficult to plan ahead. Niraparib would provide considerable relief from hospital visits, allowing women to get on with enjoying their life and planning for the future. 

These are hugely important benefits because it means women can enjoy a better quality of life, spend valuable time with their friends and family, and plan experiences they would be unable to otherwise.

Where in the UK is it currently available? 

Niraparib is available across the UK to treat women with recurrent, platinum-sensitive ovarian cancer. In England, it can also be given to ovarian cancer patients at an earlier stage of treatment - after response to first-line chemotherapy.

Visit our Patient Hub to learn more about who can access Niraparib, and other PARP inhibitors, in the UK.

What about Northern Ireland?

Northern Ireland usually follows decisions set by NICE once a drug has been fully approved. However, it does not currently approve use of drugs on the Cancer Drugs Fund. If they wait until it is fully approved by NICE, it could take up to two years before patients in Northern Ireland can access the drug.

This is yet another example of a postcode lottery when it comes to women with ovarian cancer accessing life-enhancing drugs, which is unacceptable.

In the UK women lose on average 19 years to ovarian cancer. Denying women in Northern Ireland access to a drug that can slow down disease progression down and prolong life is not acceptable. Women in Northern Ireland deserve better.

Ovarian Cancer Action is calling on the Northern Ireland Department of Health to review the situation, follow the decision of NICE and the SMC and consider putting Niraparib through its New Medicines Pathway so that women in Northern Ireland with platinum-sensitive recurrent ovarian cancer can have the same chance to access this groundbreaking, life-extending treatment as their English, Welsh and Scottish counterparts.